Cancer Prevention Pharmaceuticals, Inc. - FORM S-1/A - EX-23.1 - EXHIBIT 23.1 - February 2, 2016

Attached files

file filename
EX-3.5 - EXHIBIT 3.5 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-5.htm
EX-1.1 - EXHIBIT 1.1 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex1-1.htm
EX-3.6 - EXHIBIT 3.6 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-6.htm
EX-5.1 - EXHIBIT 5.1 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex5-1.htm
EX-3.7 - EXHIBIT 3.7 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-7.htm
EX-4.15 - EXHIBIT 4.15 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-15.htm
EX-4.18 - EXHIBIT 4.18 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-18.htm
EX-4.19 - EXHIBIT 4.19 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-19.htm
EX-4.10 - EXHIBIT 4.10 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-10.htm
EX-4.16 - EXHIBIT 4.16 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-16.htm
EX-4.17 - EXHIBIT 4.17 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-17.htm
EX-4.11 - EXHIBIT 4.11 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-11.htm
EX-10.34 - EXHIBIT 10.34 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-34.htm
EX-10.29 - EXHIBIT 10.29 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-29.htm
EX-10.32 - EXHIBIT 10.32 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-32.htm
EX-10.30 - EXHIBIT 10.30 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-30.htm
EX-10.31 - EXHIBIT 10.31 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-31.htm
S-1/A - FORM S-1/A - Cancer Prevention Pharmaceuticals, Inc.v428858_s1a.htm
EX-23.3 - EXHIBIT 23.3 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex23-3.htm
EX-10.33 - EXHIBIT 10.33 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-33.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 and related Prospectus (File No. 333-208718) dated February 2, 2016 of our report dated February 2, 2016, with respect to the consolidated financial statements of Cancer Prevention Pharmaceuticals, Inc. and Subsidiaries for the year ended December 31, 2015, and to the reference to us under the heading “Experts” in this Prospectus which is part of this Registration Statement.

 

 

/s/ Mayer Hoffman McCann P.C.

 

San Diego, California

February 2, 2016

  

 

 

Also read